Background
HPVs, or Human Papillomaviruses, stand as the predominant culprits behind sexually transmitted viral infections in humans. Specifically, contracting high-risk HPVs, such as HPV16, significantly heightens the risk of cervical cancer. The papillomavirus L1 major capsid protein, the basis of the currently marketed vaccines, self-assembles into virus-like particles (VLPs). The HPV capsid is composed of two structural proteins, L1 and L2,synthesized late in the infectious cycle. These two proteins encapsidate a histone-associated, closed circular, double-stranded DNA minichromo some. The outer shell of the virion contains 72 pentamers of L1, centered on the vertices of a T=7 icosahedral lattice. L2, a largely internal protein, is present at about 1/30 the abundance of L1. The papillomavirus major capsid protein L1 is intrinsically able to self-assemble into virus-like particles. These particles are morphologically indistinguishable from native virions and present the conformational epitopes necessary for the induction of high titers of neutralizing antibodies.
Researchers have expressed the HPV16 L1 protein in E. coli and determined its crystal structure at 3.5 A ˚ resolution. The crystallization conditions favor formation of a 12-pentamer, T=1 icosahedral assembly of L1, which they describe as a "small VLP." Assembly experiments in vitro show that a short, N-terminal segment of the L1 polypeptide chain acts as a switch between 72-pentamer, virion-like assemblies and small VLPs. The L1 subunit shave similar folded structures as their polyoma VP1 counterparts, but the modes of interpentamer association in polyoma virions and papilloma small VLPs are quite distinct. The L1structure can be used to direct engineering of chimeric VLP vaccines, locate dominant neutralizing epitopes, identify mechanisms of neutralization by antibodies, and rationalize differences among viral serotypes.
Figure 1. HPV16 L1 Monomer and Pentamer, with Polyomavirus VP1 Monomer for Comparison.
(Source: Molecular Cell. 2000.)
L1 monomer, viewed roughly normal to the five-fold axis of a pentamer. The structure includes residues 20–474; the first and last residues are labeled N(20) and C(474), respectively. Polyomavirus VP1 monomer, viewed in essentially the same direction as the L1 monomer in (A). Blue, pink, red, and green have the same significance as in the representation of L1; a C-terminal arm, "invading" from another pentamer (triple-primed letters), is yellow; the proximal part of the arm of the monomer in the figure, which extends into the neighboring pentamer, is light yellow; distalparts of this arm are not shown. L1 pentamer, viewed normal to the five-fold axis. The C-terminal projection of the central (blue) monomer is shown in yellow. L1 pentamer, viewed along the five-fold axis from outside the particle. As in (C), the C-terminal projection of the blue monomer is yellow.
References
- 1. Silvia Boschi Bazan, et al.. Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris. Arch Virol. 2009, 154:1609–1617.
- 2. Xiaojiang S. Chen, et al.. Structure of Small Virus-like Particles Assembled from the L1 Protein of Human Papillomavirus 16. Molecular Cell. 2000, Vol. 5, 557–567.
References
Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States
VACCINE
Authors: Saadeh, Kayla; Park, Ina; Gargano, Julia W.; Whitney, Erin; Querec, Troy D.; Hurley, Leo; Silverberg, Michael
Abstract
We evaluated racial/ethnic differences in prevalence of oncogenic HPV types targeted by the quadrivalent HPV vaccine (16/18) and nonavalent HPV vaccine (31/33/45/52/58) in women diagnosed with CIN2/3/AIS after quadrivalent HPV vaccine introduction (2008-2015). Typing data from 1810 cervical tissue specimen from HPV-IMPACT (Alameda County, California, US), a population-based CIN2/3/AIS surveillance effort, were analyzed. Using log-binomial regression, we calculated adjusted prevalence ratios (aPR) and 95% confidence intervals (CI) comparing type prevalence by race/ethnicity, adjusted for health insurance, age, CIN2/3/AIS grade, and time period, overall and in the "early vaccine era" (2008-2011) and "later vaccine era" (2012-2015). Overall, oncogenic HPV16/18 prevalence was significantly lower among black (43%) and Hispanic (43%) women compared with white (52%) women (aPR (95% CI): 0.80 (0.70, 0.93) and 0.80 (0.70, 0.91), respectively). In 2008-2011, proportion of HPV16/18 detected was significantly lower in black (47%), Hispanic (46%), and Asian (42%) women compared to white (58%) women (aPR (95% CI): 0.80 (0.67, 0.96), 0.75 (0.63, 0.90), and 0.73 (0.58, 0.90), respectively). There were no significant differences in 2012-2015. Between the two eras, HPV16/18 prevalence declined in white (-11%), black (-9%), and Hispanic (-6%) women, and increased in Asian women (12%). Decreasing HPV 16/18 prevalence in CIN2/3/AIS lesions in white, black, and Hispanic women may suggest benefit from quadrivalent vaccination. In our unadjusted analysis of HPV31/33/45/52/58, prevalence did not differ significantly by race/ethnicity, but was significantly higher among Hispanic women (32%) compared to white women (27%) after adjustment (aPR (95%Cl): 1.22 (1.02, 1.47). Prevalence was also non-significantly higher among black (32%) and Asian (33%) women. This analysis suggests that the nonavalent vaccine's potential for impact against cervical precancers will not be lower in women of color compared to white women. These data underscore the importance of equitable vaccination in facilitating continued declines of vaccine-preventable HPV types among all women. (C) 2019 Elsevier Ltd. All rights reserved.
Human papillomavirus 16 infection alters the Toll-like receptors and downstream signaling cascade: A plausible early event in cervical squamous cell carcinoma development
GYNECOLOGIC ONCOLOGY
Authors: Guleria, Charu; Suri, Vanita; Kapoor, Rakesh; Minz, Ranjana Walker; Aggarwal, Ritu
Abstract
Objective. Toll-like receptors constitute an important component of innate immune mechanism. HPV is a known etiological factor of cervical cancer and is known to interfere with the expression of TLRs and downstream signaling pathway. It remains poorly understood whether HPV modulates the expression of TLRs. Hence, understanding HPV mediated immune alterations might aid in identifying novel therapeutic targets. The aim was to study the relative gene expression of TLRs & downstream signaling pathway in cervical carcinoma. Methods. Cervical squamous cell carcinoma (CSCC) and normal cervical tissues were obtained. Subsequent to HPV genotyping, mRNA expression profiling using PCR Array was performed. Protein expression of relevant genes with western blot was studied. Levels of cytokines in cervicovaginal washes were estimated using a Luminex multiplex platform. Results. All cases of cervical cancer were HR-HPV positive and predominant subtype was HPV16 (71.1%). Significant TLR4 upregulation and TLR2,7 downregulation were observed in HR-HPV infected cervix. TLR4,7 demonstrated low expression in CSCC. Molecules from cancer allied pathways; RELA, AKT, CDKN2A, and MDM2 demonstrated upregulation in CSCC. Protein expression data corroborated with gene expression profile. A diminished level of Thl cytokines TNF-alpha, IFN-gamma, IL-17, and IL-12 was observed in CSCC. Significantly increased levels of IL-1 beta, IL-6 and IL-2 were detected in HR-HPV infected cervix. Kaplan Meier curve demonstrated high TLR4 and low TLR7 expression was associated with poor prognosis. Conclusion. The study demonstrates the HPV mediated dampening of the innate immune response in CSCC and provides support for exploring potential TLR2, 7 agonists as an adjunct therapy in CSCC patients. (C) 2019 Elsevier Inc. All rights reserved.